Recent Articles
Immutep (ASX: IMM) Hits Key Phase III Milestone: Buy the Dip or Take Profits Before the Critical Data Readout?
Immutep (ASX: IMM) has pulled…
EOS (ASX: EOS) Crashes 46% From All-Time High After Short Seller Attack- Buying Opportunity or Time to Run?
Electro Optic Systems (ASX: EOS)…
Lotus Resources (ASX:LOT) Drops 28% After $76M Raise- Is the Dip a Buy or a Dilution Warning?
Lotus Resources (ASX: LOT) shares…
Amazon (NASDAQ:AMZN) Down 9%, Is Capex Becoming the Story?
14% Sales Growth, 128B Spend,…
The proposed Rio Tinto Glencore merger failed, here’s why and what it means for the companies!
The proposed Rio Tinto Glencore…
Tech and AI Stocks Sell Off, This Reckoning Was Always Coming
The Tech and AI Valuation…
SKS Technologies (ASX:SKS) Surges 8% on A$60M Contract Wins and FY26 Guidance Upgrade- Buy or Take Profits?
SKS Technologies jumps on new…
Does your stock suffer from governance issues? Here are 10 hidden red flags!
No investor would invest in…
Are ASX Uranium Stocks a Buy After Falling up to 10%? Here’s What the AMD Selloff Really Means
ASX uranium stocks fell after…
Beach Energy (ASX:BPT) Slides 4% on Weaker Half-Year Profit- Is the Dip a Buying Opportunity as Waitsia Ramps Up?
Beach Energy dips on profit,…
MAAS Group (ASX:MGH) Plunges 27% After Selling Its Strongest Division for $1.7B- Buy the Dip or Avoid?
MAAS Group drops 27% after…
AMD (NASDAQ:AMD) 20% Down in a Week, Reset Opportunity or Start of a De Rating?
The Sell Off Isn’t About…
Why Are Tech and SaaS Stocks Selling Off Right Now?
Why Are Tech and SaaS…
The 50% CGT discount on shares: Here’s how it works, and if it is under threat
The 50% CGT discount on…
PYC Therapeutics (ASX:PYC): Its been raising ~$650m to fund 4 clinical assets for multiple years!
PYC Therapeutics (ASX:PYC) is currently…
Brazilian Rare Earths (ASX:BRE) Rises as Monte Alto Ore Sorting Delivers 95% Yields: Time to Buy?
Brazilian Rare Earths jumps after…
DataWorks Group (ASX:DWG) Secures C$12.5M Contract Boost: Time to Buy This Micro-Cap?
DataWorks Group surges after Ontario…
Island Pharmaceuticals (ASX:ILA) Raises A$9M as FDA Confirms Galidesivir Pathway: Is This Small-Cap Biotech a Buy?
Island Pharmaceuticals jumps after FDA…
Trump’s $12 Billion ‘Project Vault’ : 6 ASX Rare Earth Stocks Set to Benefit
ASX rare earth stocks jump…
Find Us in
Stocks Down Under Analysts delve into a large variety of ASX-listed stocks and sectors.
Sector Analysis
The Best Mining Stocks
Mining and resources stocks have substantial potential given demand for all types of resources and metals from gold and iron ore to battery metals like lithium and graphite! There are over 700 stocks in this sector from big miners to small cap explorers.
The Best Tech Stocks
Tech stocks are appetising in the context of an increasingly digital world ranging from data centre builders, cloud services providers and cybersecurity companies. Many of the ASX's best performing stocks in the last decade have been tech stocks.
The Best Uranium Stocks
Uranium stocks are in a good spot right now with rising demand for clean energy, nuclear energy making a comeback and yellowcake pricing reaching levels not seen since the GFC. This has enabled many companies with mothballed projects to bring them out of hibernation.
The Best Healthcare Stocks
There are dozens of Healthcare stocks on the ASX ranging from big names like CSL and Cochlear with established products and markets, to small cap biotechs and medtechs hoping to follow in their footsteps and commercialise the next big innovation.
The Best Mining Stocks
The Best Tech Stocks
The Best Uranium Stocks
Share Type Analysis
The Best ASX Stocks Right Now
The quest for the best stocks to buy now is a never-ending one, but armed with a solid investment strategy, you can create a diversified portfolio that stands the test of time. We provide our Top 10 ASX stocks we think investors should consider right now.
The Best ASX Stocks Right Now
The Top Penny Stocks
Navigating ASX Penny stocks, can be complex, given the diversity of companies operating in various sectors and the high risk associated with them. But there is potential for impressive returns if investors can find the right company.
The Top Penny Stocks
The Top Dividend Stocks
Investing in Dividend stocks can provide an additional source of income, and so are popular with a wide variety of investors. But only some companies pay dividends, and even consistent payers can fluctuate payouts year to year. We outline the Top Dividend Stocks for investors to consider.
The Top Dividend Stocks
Top ASX Index Funds
Explore our comprehensive analysis of the top ASX index funds, carefully curated by industry experts. Discover which funds are currently outperforming and why, based on detailed market trends and performance metrics. Ideal for both new and seasoned investors seeking strategic investment opportunities on the ASX. Dive into our report today to make informed investment decisions.
Top ASX Index Funds
The Top Blue Chip Stocks
Discover the best ASX blue chip stocks for investment. Our industry experts provide in-depth analysis on these well-established companies with strong credit ratings and a long history of performance and stability. Explore market leaders like Commonwealth Bank of Australia, BHP Group Ltd, and National Australia Bank Limited.
The Top Blue Chip Stocks
Top ASX Growth Stocks for Investing
Explore our comprehensive analysis of the top ASX growth stocks for investing. Our industry experts have curated a detailed report on the most promising opportunities available in the market. Whether you're a seasoned investor or just starting out, our insights provide valuable information to help you make informed decisions.
Top ASX Growth Stocks for Investing
Webinars and Interviews
DorsaVi (ASX:DVL) unveiled its ambitious 22nm ReRAM strategy: Interview with Group CEO Mathew Regan
DorsaVi (ASX:DVL) is switching into high gear We spoke to DorsaVi’s Group CEO, Mat Regan, about…
Unicycive Therapeutics (Nasdaq:UNCY) has big plans for its lead candidate OLC
Unicycive Therapeutics (Nasdaq:UNCY) Unicycive Therapeutics is a clinical-stage biotech company based in Los Altos, CA. The…
Weebit Nano signs license deal with Texas Instruments: Interview with CEO Coby Hanoch
Weebit Nano bags an analog elephant We spoke with CEO Coby Hanoch about the license deal…
Chimeric Therapeutics (ASX:CHM) is headed for the CAR-T ‘Big Time’
Chimeric Therapeutics (ASX:CHM) We spoke to Dr Rebecca McQualter, CEO of Chimeric Therapeutics (ASX:CHM), about the…
Investment Glossary
What Is a Small Cap Company? A Complete Guide for Investors
Overview of Small Cap Companies…
What is the All Ordinaries Index and How Does It Work?
The All Ordinaries Index, also…
What is Commodity? Understanding Commodity Trading
Introduction to Commodities Commodities are…
Overview of Securities in the Australian Financial Market
What is a security? Security refers…
What Is an IPO? Understanding Initial Public Offerings
What is IPO? An Initial Public…
The Team Behind Stocks Down Under
Stuart Roberts
Co-Founder
Stuart Roberts is the co-founder of Stocks Down Under. Previously, Stuart covered the healthcare and biotechnology sectors at NDF Research and at stockbroking firms Southern Cross Equities, Bell Potter and Baillieu Holst from 2002 to 2015, where he developed a reputation for detailed analysis on previously uncovered Life Science companies. In 2018, he co-founded Pitt Street Research
Marc Kennis
Co-Founder
Marc is the co-founder of Stocks Down Under and has 25+ years experience analyzing companies in a range of sectors, including Food & Beverage, Industrials, Technology, Medical Equipment, Telecom and Media. Prior to moving to Australia in 2014, he worked for a number of brokers and banks in The Netherlands, including ING and Rabobank. In 2018, Marc co-founded Pitt Street Research,
The Team Behind Stocks Down Under
STUART ROBERTSStuart Roberts is the co-founder of Stocks Down Under. Previously, Stuart covered the healthcare and biotechnology sectors at NDF Research and at stockbroking firms Southern Cross Equities, Bell Potter and Baillieu Holst from 2002 to 2015, where he developed a reputation for detailed analysis on previously uncovered Life Science companies. In 2018, he co-founded Pitt Street Research together with Marc.
MARC KENNISMarc is the co-founder of Stocks Down Under and has 20+ years experience analyzing companies in a range of sectors, including Food & Beverage, Industrials, Technology, Medical Equipment, Telecom and Media. Prior to moving to Australia in 2014, he worked for a number of brokers and banks in The Netherlands, including ING and Rabobank. In 2018, Marc co-founded Pitt Street Research, Australia's preeminent issuer-sponsored equities research firm.
PETER KILBYPete is Stocks Down Under's head of customer service. He is an avid investor with a knack for deep-dive company research. Pete likes the more established companies on ASX, but doesn't shy away from the occasional risky play. At Stocks Down Under he gets to do the two things he loves most, investing and talking to like-minded people.
Get in touch
contact@stocksdownunder.com
Follow us on